GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Notes Receivable

Yumanity Therapeutics (FRA:8IY) Notes Receivable : €0.00 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Notes Receivable?

Yumanity Therapeutics's Notes Receivable for the quarter that ended in Sep. 2022 was €0.00 Mil.


Yumanity Therapeutics Notes Receivable Historical Data

The historical data trend for Yumanity Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Notes Receivable Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Notes Receivable
- - -

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Yumanity Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Yumanity Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines